Delivery Order SPE2DB22D2206-SPE2DB25FJV06
- Not listed
- The Defense Logistics Agency (DLA) awarded a $3,061.96 delivery order to AmerisourceBergen Drug Corp for LINZESS 145 micrograms capsules (30-count units) on September 9, 2025, with completion targeted for September 10, 2025. This firm fixed price contract represents a non-competitive delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The award supports the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Linzess 72 mg capsules in a 30-count unit pack, with a contract ceiling value of $1,495.59 and an ultimate completion date of July 21, 2025. This firm fixed price delivery order represents a non-competitive award and is classified as a child contract under AmerisourceBergen's larger federal contracting framework. The performance location is the company's corporate office in...
- The Defense Logistics Agency awarded a delivery order valued at $1,909.80 to AmerisourceBergen Drug Corp for Linzess 72 microgram capsules (30-count units) on September 3, 2025, with an ultimate completion date of September 4, 2025. This competitive award, which carries no set-aside designation, represents a firm fixed-price delivery order for pharmaceutical supply to support federal medical procurement needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $1,423.44 to supply Linzess 72 microgram capsules (30-count units) under a firm fixed price contract. The award, issued on August 28, 2025, with an ultimate completion date of August 29, 2025, represents a non-competitive, non-set-aside delivery order. The product will be delivered to Conshohocken, Pennsylvania, the location of AmerisourceBergen's corporate headquarters. This delivery order is issued...
- The Defense Logistics Agency awarded a $11,335.78 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Linzess 290 microgram capsules in quantities of 30 units. This firm fixed-price contract represents a competitively awarded, non-set-aside procurement with a completion date of August 19, 2025. The product will be performed and delivered from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $10,909.98 to AmerisourceBergen Drug Corp for LINZESS 72 mcg capsules (30-count units) on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a delivery order valued at $1,064.49 to AmerisourceBergen Drug Corp for Linzess 290 microgram capsules (30-count units) on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions...
- The Defense Logistics Agency awarded a delivery order valued at $2,333.53 to AmerisourceBergen Drug Corp for Linzess 72 mcg capsules (30-count units) on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed-price delivery order was performed at the contractor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating it was competed among all eligible vendors in the open market. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for LINZESS 145 MCG capsules (30-count units) with a ceiling value of $1,562.53. This non-set-aside, competitively awarded contract represents a firm fixed-price delivery order with an ultimate completion date of August 26, 2025. The award was issued on August 25, 2025, with performance to be fulfilled at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp valued at $2,386.99 for the supply of Linzess 145 mcg capsules (30-unit quantity) with an ultimate completion date of August 5, 2025. This contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open procurement. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJV06Delivery Order
The Defense Logistics Agency awarded a $6,580.09 firm fixed price delivery order to AmerisourceBergen Drug Corp for LINZESS 145 MCG capsules (30-count units) with an ultimate completion date of September 9, 2025. This non-set-aside competitive award was issued to AmerisourceBergen's Corporate Office, headquartered in Conshohocken, Pennsylvania, which serves as a critical pharmaceutical distributor for federal medical procurement. The delivery order represents a single transaction under AmerisourceBergen's larger contract vehicle with DLA. This delivery order is a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The prime IDC functions as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a wide range of medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare programs worldwide. LINZESS, a gastrointestinal medication, exemplifies the type of specialty pharmaceutical products the company delivers to Defense Health Agency customers and other government healthcare systems through this flexible contract mechanism.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.6k | 9/8/25 |